Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / Shares of Teladoc Health were in the red on Monday after its CFO and COO sold off a big stake of his shares. Shares of Clearside Biomedical were also in the red on disappointing trial results. RDI Initiates Coverage on: Teladoc Health, Inc...
ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its third quarter 2018 financial results wi...
More news on: Datawatch Corporation, JinkoSolar Holding Co., Ltd., Yulong Eco-Materials, , Stocks on the move, Read more ...
Clearside Biomedical (NASDAQ: CLSD ) -51% on SAPPHIRE Phase 3 study failing to meet its primary endpoint. More news on: Clearside Biomedical, Diana Containerships Inc., Sysco Corporation, Stocks on the move, , Top stock market news, Read more ...
Thinly traded micro cap Clearside Biomedical (NASDAQ: CLSD ) is down 27% premarket on light volume in response to its announcement that a Phase 3 clinical trial, SAPPHIRE , evaluating XIPERE (formerly suprachoroidal CLS-TA) in patients with retinal vein occlusion failed to ach...
- Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 - - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week Topline Data - ALPHARETTA, Ga., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceuti...
"Wine makes all things possible .” ― George R.R. Martin, The Mystery Knight Today, we look at a small biotech concern that a few followers have asked about lately. We have updated some previously exclusive research provided on this name to Biotech Forum members last month wi...
ALPHARETTA, Ga., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that additional data from PEACHTREE, the c...
ALPHARETTA, Ga., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced the appointment of Thomas A. Ciulla, M.D., M.B.A...
ALPHARETTA, Ga., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that two presentations scheduled to be given at ...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...